Who won Per- and Poly-fluoroalkyl substance exposure, emissions, and end of… 2025? 69 companies funded
- 1funded projects
- €23.4MEU contribution
- 69companies, 7 SMEs
- 13countries
Grant topic: Per- and Poly-fluoroalkyl substance (PFAS) exposure, emissions, and end of life management in the healthcare sector
The European Commission funded 1 project under the Horizon Europe topic HORIZON-JU-IHI-2025-10-03-two-stage, with €23.4M in total EU contribution. 69 private companies from 13 countries took part, and 7 of them are SMEs. Below is who they are, what they are building, and how much each received.
At a glance
- Funded projects: 1
- Total EU contribution: €23.4M
- Of which to companies: €1.2M (5%)
- Companies / of which SMEs: 69 / 7
- Average consortium size: 89.0 organisations
- Projects coordinated by a company: 0 of 1
- Top countries (company participations): Germany (17), the United States (11), Switzerland (8), France (8)
Companies that received funding
Polysecure GmbH
Freiburg Im Breisgau, Germany · SME
Received €849K as a participant in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Medicalmountains GmbH
Tuttlingen, Germany
Received €351K as a participant in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Merck Life Science Kgaa
Darmstadt, Germany
Received €0 as a associatedPartner in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Bayer Healthcare Llc
Whippany, the United States
Received €0 as a associatedPartner in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Cilag GmbH International
Zug, Switzerland
Received €0 as a associatedPartner in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Abbvie Deutschland GmbH & Co KG
Wiesbaden, Germany · website
Received €0 as a associatedPartner in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Lilly Deutschland GmbH
Bad Homburg, Germany
Received €0 as a associatedPartner in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Astrazeneca Uk Limited
Cambridge, the United Kingdom · website
Received €0 as a participant in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Abbvie Inc
North Chicago, the United States · website
Received €0 as a participant in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Sanofi-Aventis Deutschland GmbH
Frankfurt Am Main, Germany · website
Received €0 as a participant in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Medical Devices & Diagnostics Global Services, LLC
Bridgewater, the United States
Received €0 as a associatedPartner in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Glaxosmithkline Research & Development Limited
London, the United Kingdom · website
Received €0 as a participant in PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare (2026-09 to 2031-08).
Also funded: Sanofi Winthrop Industrie (FR), Boehringer Ingelheim Corporate Center GmbH (DE), UCB Biopharma (BE), Janssen Sciences Ireland UC (IE), Edwards Lifesciences Llc (US), Sanofi Genzyme (US), Pfizer Healthcare India Private Limited (IN), UCB Pharma SA (BE), Novartis Pharma AG (CH), Edwards Lifesciences BV (NL), PFIZER Ireland Pharmaceuticals (IE), Merck Santé S.A.S. (FR), Inopsys (BE), ION Beam Applications SA (BE), F. Hoffmann-La ROCHE AG (CH), Merck S.L.U. (ES), Olympus Winter & Ibe GmbH (DE), Gilead Sciences Inc (US), Mura Technology Limited (UK), Boehringer Ingelheim Pharma GmbH &co KG (DE), ElringKlinger Kunststofftechnik GmbH (DE), Oril Industrie (FR), Merck Kommanditgesellschaft Auf Aktien (DE), Biotronik SE & Co. KG (DE), Richard Wolf GmbH (DE), Merck Serono SA (CH), Medical Device Business Services Inc (US), Edwards Lifesciences Belgium BV (BE), Sanofi US Services Inc. (US), Boehringer Ingelheim Internationalgmbh (DE), Edwards Lifesciences GmbH (DE), Merck Serono SpA (IT), Terumo Europe (BE), Pfizer Italia s.r.l. (IT), Ares Trading SA (CH), Bayer Consumer Care AG (CH), Edwards Lifesciences SL (ES), Johnson & Johnson Services, Inc. (US), Pfizer Inc (US), Technologie Servier (FR), and 17 more.
The funded projects
PFAROS: Driving Sustainable Innovation to Minimise PFAS in European Healthcare
€23.4M EU contribution · 89 partners · 2026-09 to 2031-08 · coordinated by Universiteit Gent (BE)
PFAROS is our European game-changing initiative to accelerate the transition away from harmful PFAS substances in the pharmaceutical and medical technology sectors. Aligned with EU public health, environmental, and industrial policy objectives, PFAROS is developing safe, scalable, and regulatory-ready alternatives, ensuring that healthcare innovation and sustainability go hand in hand.PFAROS’ mission is to replace…
What the winning consortia had in common
- Consortia averaged 89.0 organisations, and companies held 69 of 89 seats (78%).
- 10% of company seats went to SMEs, so smaller firms clearly had room in these consortia.
- 0 of 1 projects were coordinated by a company; the rest were led by universities, research organisations or public bodies.
See the original call on Grantalist.
Source: CORDIS Horizon Europe open data, © European Union, reused under CC BY 4.0. Figures are the EU contribution recorded at grant signature; data as of 2026-08-28.